Company news
Zymeworks Inc. news in 2022
Zymeworks Inc.'s news releases, calls and decks from 2022, newest first.
Zymeworks Announces Positive Topline Data in the Pivotal HERIZON-BTC-01 Trial of Zanidatamab
December 18, 2022
Zymeworks to Transfer Stock Listing to Nasdaq
December 4, 2022
Zymeworks Announces Expiration of Hart-Scott-Rodino Waiting Period for Zanidatamab License Agreement with Jazz Pharmaceuticals
November 28, 2022
Zymeworks Announces Abstract For Zanidatamab In Late-Line HER2-Positive Hormone-Receptor Positive (HR+) Metastatic Breast Cancer At The San Antonio Breast Cancer Symposium (SABCS)
November 20, 2022
Zymeworks Provides Corporate Update and Reports Third Quarter 2022 Financial Results
November 7, 2022
Zymeworks Early R&D Day Highlights Progress in Development of Novel Pipeline Assets and Applications of Proprietary Next-Generation Technology Platforms
October 19, 2022
Zymeworks Completes Plan to Become Delaware Corporation
October 12, 2022
Zymeworks Announces Results of Special Meeting
October 6, 2022
Zymeworks Reminds Shareholders to Vote FOR its Redomicile
October 3, 2022
Zymeworks Reports Preliminary Phase 1 Trial Results for Zanidatamab Zovodotin (ZW49) at European Society for Medical Oncology Annual Congress
September 11, 2022
Zymeworks Announces Filing and Mailing of Materials for the Special Meeting to Approve Redomicile to Delaware
September 7, 2022
Zymeworks Announces Release of ESMO Abstract for Phase 1 Study of Zanidatamab Zovodotin (ZW49) in Solid Cancers
September 3, 2022
Zymeworks Provides Corporate Update and Reports Second Quarter 2022 Financial Results
August 3, 2022
Zymeworks Announces Oral Presentation of Data from Phase 1 Study of Zanidatamab Zovodotin (ZW49) in Solid Cancers at European Society for Medical Oncology (ESMO) Congress 2022 in Paris
July 24, 2022
Zymeworks Reports Inducement Grant to New Chief Scientific Officer
July 21, 2022
Zymeworks Announces Plan to Become a Delaware Corporation
July 14, 2022
Zymeworks Appoints Dr. Paul Moore as Chief Scientific Officer
June 26, 2022
Zymeworks Adopts Limited-Duration Shareholder Rights Plan, Enabling All Shareholders to Realize Full Value of Company
June 9, 2022
Zymeworks Announces Participation in Upcoming Investor Conference
May 26, 2022
Zymeworks’ Board of Directors Unanimously Rejects Unsolicited, Non-Binding Proposal
May 19, 2022
Zymeworks Provides Corporate Update and Reports First Quarter 2022 Financial Results
May 3, 2022
Zymeworks Reports Last Patient Enrolled in Pivotal Study of Zanidatamab in Treatment of HER2-Expressing Late-Line Biliary Tract Cancer
April 27, 2022
Zymeworks Announces Presentations at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
April 26, 2022
Zymeworks to Host First Quarter 2022 Results Conference Call
April 18, 2022
Zymeworks Provides Corporate Update and Reports Year-End 2021 Financial Results
February 23, 2022
Zymeworks to Host Fourth Quarter and Full Year 2021 Results Conference Call
February 7, 2022
Zymeworks Announces Closing of Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
January 30, 2022
Zymeworks Announces Pricing of $100.0 Million Public Offering
January 25, 2022
Zymeworks Provides Corporate Update on Key Strategic Priorities and Outlook for 2022
January 18, 2022
Zymeworks Reports Inducement Grant Under New York Stock Exchange Listed Company Manual Rule
January 14, 2022
Zymeworks Names Biotechnology Industry Leader Kenneth Galbraith as Chair and CEO to Succeed Dr. Ali Tehrani
January 4, 2022
Decks in 2022
- Merger or Acquisition (July 2022)
Merger or acquisition · 10 slides · Jul 15, 2022